Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of HBsAg Vaccine Formulations and Adjuvant Systems
NCT00805389Phase 2Completed
- Sponsor
- GSK
- Start
- Dec 2008
- Primary completion
- Sep 2010
- Modality
- Whole Inactivated Vaccines
- Countries
- 2
01
Overview
Phase 2, randomised, single-blind trial of GSK223192A in hepatitis B (HBV) (5 arms), sponsored by GSK. Primary endpoint: Number of Hepatitis B (HB)-Specific Cluster of Differentiation 4 (CD4+) T Cells at Day 44. Started Dec 2008; status: completed.
02
Drugs
GSK223192A
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT00805389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00805389.